SAN DIEGO, Jan. 16, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today provided an update on its business…
